AV Fistula Clinical Trial
Official title:
A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access
The Objectives of this study are:
1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional
maturation when administered during the maturation process compared with placebo.
2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary
procedures to aid in fistula maturation compared with placebo.
3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for
hemodialysis compared with placebo.
This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be
conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will
be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health
Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The
investigators expect to enroll 128 patients. Patients will be assigned to treatment groups
with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation.
Patients will be stratified based on fistula location (lower arm versus upper arm).
Objectives:
1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional
maturation when administered during the maturation process compared with placebo.
2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary
procedures to aid in fistula maturation compared with placebo.
3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for
hemodialysis compared with placebo.
This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be
conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will
be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health
Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The
investigators expect to enroll 128 patients. Patients will be assigned to treatment groups
with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation.
Patients will be stratified based on fistula location (lower arm versus upper arm).
Participation in this study will not affect standard care of patients with AV fistulae
receiving hemodialysis. The only additional treatment is administration of the study drug or
placebo and additional monitoring, including one additional ultrasound, for 6 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05462223 -
Alucent Vessel Restoration System for AVF
|
N/A | |
Completed |
NCT02363972 -
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
|
N/A | |
Terminated |
NCT04626427 -
The WavelinQâ„¢ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation
|
N/A | |
Completed |
NCT01471041 -
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05569109 -
av Fistula Patency Loss as a Cause of Fistula Failure and Hyperphosphatemia
|
||
Active, not recruiting |
NCT04484220 -
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
|
N/A | |
Active, not recruiting |
NCT04327609 -
SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications
|
N/A |